Stock Market News
Omega Diagnostics' full-year results meet targets
23-06-2014 07:37
Add To Google +1 | Tweet |
- Adjusted pre-tax profit surges 41%
- Strong performance from food intolerance division
- Positive about future prospects
Medical diagnostics company Omega reported a surge in full-year adjusted pre-tax profit after a robust performance from its food intolerance division and said it remains positive about future trading.
Adjusted pre-tax profit soared 41% to £1.10m for the year ended March 31st while turnover firmed 3% to £11.6m. The Scotland-based group said it was encouraged by prospects for its Visitect CD4 HIV testing kit which is now well into its field trials.
Adjusted earnings per shares fell to 1.2p from 1.3p previously. Gross profit for the period rose 5% to £7.4m.
Among its main divisions, Food Intolerance revenue rose 18% to £5.18m, Allergy and autoimmune revenue slipped 5% to £3.96m while Infectious disease/other revenue dropped 10% to £2.45m.
Chairman David Evans said: "Our future landscape is brightened, as well as dominated, by the prospects for our Visitect CD4 test, which is now well into its field trials. However, we all have a dislike for complete uncertainty and that is our challenge in being able to set our budgets for the current year in relation to both the timing and quantum of CD4 revenues.
"We will make significant progress this year in terms of gaining market acceptance for CD4 and I believe the prospects for the group remain positive."
CJ
- Strong performance from food intolerance division
- Positive about future prospects
Medical diagnostics company Omega reported a surge in full-year adjusted pre-tax profit after a robust performance from its food intolerance division and said it remains positive about future trading.
Adjusted pre-tax profit soared 41% to £1.10m for the year ended March 31st while turnover firmed 3% to £11.6m. The Scotland-based group said it was encouraged by prospects for its Visitect CD4 HIV testing kit which is now well into its field trials.
Adjusted earnings per shares fell to 1.2p from 1.3p previously. Gross profit for the period rose 5% to £7.4m.
Among its main divisions, Food Intolerance revenue rose 18% to £5.18m, Allergy and autoimmune revenue slipped 5% to £3.96m while Infectious disease/other revenue dropped 10% to £2.45m.
Chairman David Evans said: "Our future landscape is brightened, as well as dominated, by the prospects for our Visitect CD4 test, which is now well into its field trials. However, we all have a dislike for complete uncertainty and that is our challenge in being able to set our budgets for the current year in relation to both the timing and quantum of CD4 revenues.
"We will make significant progress this year in terms of gaining market acceptance for CD4 and I believe the prospects for the group remain positive."
CJ
Related share prices |
---|
Omega Diagnostics Group (ODX) share price |
Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and conditions of useage of this data. Republication or redistribution of content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd.
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- RBS share price
- Diageo share price
- Standard Life Share Price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- Morrisons Share Price
- Aviva Share Price
- LGO Share price
- Tullow Oil Share Price
- SXX Share Price
- Easyjet Share Price
- Next Share Price
- Thomas Cook Share Price
- SSE Share Price
- IAG Share Price
- Bat share price
- Monitise Share Price
- Kingfisher share price
- Dragon Oil share price
- UKOG share price
- SOLG share price